Publication | Closed Access

Phase II Trial of Gefitinib in Combination with Bevacizumab as First-Line Therapy for Advanced Non–Small Cell Lung Cancer with Activating EGFR Gene Mutations: The Okayama Lung Cancer Study Group Trial 1001

First-line TherapyPhase Ii TrialMedicinePathologyBronchial NeoplasmCancer TreatmentOncologyRadiation OncologyLung CancerMolecular OncologyCancer Growth